希少疾患治療薬の世界市場（2022年版） - 薬剤タイプ、治療領域、患者、投与経路、流通チャネル、地域別、国別の分析（2022年版）。市場インサイト、COVID-19の影響を考慮した予測（2022-2027年）。

Global Rare Disease Drugs Market (2022 Edition) – Analysis By Drug Type, Therapeutic Area, Patients, Route of Administration, Distribution Channel, By Region, By Country (2022 Edition): Market Insights, and Forecast with Impact of COVID-19 (2022-2027)

エグゼクティブサマリー Azoth Analyticsの調査レポートによると、世界の希少疾患治療薬は2021年に1,471億米ドルと評価されました。研究活動や新規治療薬の開発への注目が高まっていることが、希少疾患治療薬... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2022年5月31日	US$2,400 シングルユーザーライセンスライセンス・価格情報注文方法はこちら	290	英語

サマリー

エグゼクティブサマリー

Azoth Analyticsの調査レポートによると、世界の希少疾患治療薬は2021年に1,471億米ドルと評価されました。研究活動や新規治療薬の開発への注目が高まっていることが、希少疾患治療薬市場の成長を促しています。また、製品開発の活発化により、希少遺伝性疾患の診断に技術主導の革新的なデバイスの導入が進んでいます。

さらに、希少疾患の治療に関する意識向上を目的とした政府の好意的な政策により、希少疾患の効果的な治療法の採用が進んでいます。しかし、患者数の少なさ、病態や進行の理解不足、確立されたエンドポイントの欠如など、希少疾患の医薬品開発における効率的かつ効果的な臨床試験の妨げとなる要因がいくつか存在します。そのため、複数の規制機関が、患者の安全性と薬剤の有効性を確保するために、希少疾患の医薬品承認に関する規制基準の実施に取り組んでいます。

さらに、希少疾病の発見率の向上と診断率の上昇は、コスト上昇の要因になると考えられます。希少疾病治療が人道的に有益であることは議論の余地がありませんが、高い治療費に関する懸念は、支払者がどのように医療給付を管理・運用するかに大きな影響を与え、最終的に希少疾病治療薬を患者が利用できるかどうかを決定することになります。さらに、生物学的製剤は、先進国において高い有病率を示す癌などの希少疾病の治療に使用され、副作用が少ないことが特徴です。

報告書の範囲

- 本レポートでは、2017-2021年の過去期間と2022-2027年の予測期間における希少疾患治療薬市場の分析をご紹介しています。

- 本レポートでは、希少疾患治療薬市場を金額（10億米ドル）別に分析しています。

- 希少疾患治療薬市場を薬剤タイプ別（生物学的製剤、非生物学的製剤）に分析したレポートです。

- 希少疾患治療薬市場を治療領域別（感染症、腫瘍、神経、代謝、その他）に分析したレポートです。

- 希少疾患治療薬市場を患者別（小児、成人）に分析したレポートです。

- 希少疾患治療薬の市場を投与経路別（経口、注射）に分析したレポートです。

- 希少疾患治療薬市場を流通チャネル（病院・小売薬局、オンライン薬局）別に分析したレポートです。

- 希少疾患治療薬の世界市場を地域別（北米、欧州、アジア太平洋地域、LAMEA）に分析しています。

- 希少疾患治療薬の世界市場を国別に分析（米国、カナダ、ドイツ、イギリス、フランス、イタリア、中国、日本、インド、韓国）。

- 市場の魅力は、地域別、薬剤タイプ別、治療分野別、患者別、投与経路別、流通チャネル別で提示されています。

- また、業界の主な機会、トレンド、ドライバー、課題についても分析されています。

- 競合の開発、戦略、M&A、新製品開発などを追跡しています。

- 本レポートで分析されている企業は、武田薬品工業株式会社、サノフィ、Merck KGaA、F. Hoffman-La Roche Ltd.、ファイザー、Novartis AG、バイエルグループ、バイオジェン、グラクソ・スミスクライン、AbbVie Inc.ほかです。

主なターゲットオーディエンス

- 希少疾病用医薬品メーカー

- 医療・製薬企業

- コンサルティング・アドバイザリーファーム

- 政府・政策担当者

- 規制当局

ページTOPに戻る

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Rare Disease Drugs Market: Product Outlook

4. Global Rare Disease Drugs Market: Sizing and Forecast

4.1 Global Rare Disease Drugs Market Size, By Value, 2017-2027

4.2 Impact of COVID-19 on Global Rare Disease Drugs Market

5. Global Rare Disease Drugs Market Segmentation – By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel

5.1 Competitive Scenario of Global Rare Disease Drugs Market: By Drug Type

5.1.1 Biologics – Market Size and Forecast (2017-2027)

5.1.2 Non-Biologics – Market Size and Forecast (2017-2027)

5.2 Competitive Scenario of Global Rare Disease Drugs Market: By Therapeutic Area

5.2.1 Infectious disease – Market Size and Forecast (2017-2027)

5.2.2 Oncology– Market Size and Forecast (2017-2027)

5.2.3 Neurological - Market Size and Forecast (2017-2027)

5.2.4 Metabolic – Market Size and Forecast (2017-2027)

5.2.5 Others - Market Size and Forecast (2017-2027)

5.3 Competitive Scenario of Global Rare Disease Drugs Market: By Patients

5.3.1 Paediatric – Market Size and Forecast (2017-2027)

5.3.2 Adults - Market Size and Forecast (2017-2027)

5.4 Competitive Scenario of Global Rare Disease Drugs Market: By Route of Administration

5.4.1 Oral – Market Size and Forecast (2017-2027)

5.4.2 Injectable - Market Size and Forecast (2017-2027)

5.5 Competitive Scenario of Global Rare Disease Drugs Market: By Distribution Channel

5.5.1 Hospitals & Retail Pharmacies– Market Size and Forecast (2017-2027)

5.5.2 Online Pharmacies - Market Size and Forecast (2017-2027)

6. Global Rare Disease Drugs Market: Regional Analysis

6.1 Competitive Scenario of Global Rare Disease Drugs Market: By Region

7. North America Rare Disease Drugs Market: An Analysis (2017-2027)

7.1 North America Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

7.2 North America Rare Disease Drugs Market – Prominent Companies

7.3 Market Segmentation By Drug Type (Biologics, Non-Biologics)

7.4 Market Segmentation By Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic and Others)

7.5 Market Segmentation By Patients Type (Pediatric, Adults)

7.6 Market Segmentation By Route of Administration (Oral, Injectable)

7.7 Market Segmentation By Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)

7.8 North America Rare Disease Drugs Market: Country Analysis

7.9 Market Opportunity Chart of North America Rare Disease Drugs Market - By Country, By Value, 2027

7.10 Competitive Scenario of North America Rare Disease Drugs Market: By Country

7.11 United States Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

7.12 United States Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

7.13 Canada Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

7.14 Canada Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

8. Europe Rare Disease Drugs Market: An Analysis (2017-2027)

8.1 Europe Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

8.2 Europe Rare Disease Drugs Market – Prominent Companies

8.3 Market Segmentation By Drug Type (Biologics, Non-Biologics)

8.4 Market Segmentation By Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic, Others)

8.5 Market Segmentation By Patients Type (Pediatric, Adults)

8.6 Market Segmentation By Route of Administration (Oral, Injectable)

8.7 Market Segmentation By Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)

8.8 Europe Rare Disease Drugs Market: Country Analysis

8.9 Market Opportunity Chart of Europe Rare Disease Drugs Market - By Country, By Value, 2027

8.10 Competitive Scenario of Europe Rare Disease Drugs Market: By Country

8.11 Germany Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

8.12 Germany Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

8.13 United Kingdom Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

8.14 United Kingdom Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

8.15 France Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

8.16 France Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

8.17 Italy Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

8.18 Italy Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

9. Asia Pacific Rare Disease Drugs Market: An Analysis (2017-2027)

9.1 Asia Pacific Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

9.2 Asia Pacific Rare Disease Drugs Market – Prominent Companies

9.3 Market Segmentation By Drug Type (Biologics, Non-Biologics)

9.4 Market Segmentation By Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic, Others)

9.5 Market Segmentation By Patients Type (Pediatric, Adults)

9.6 Market Segmentation By Route of Administration (Oral, Injectable)

9.7 Market Segmentation By Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)

9.8 Asia Pacific Rare Disease Drugs Market: Country Analysis

9.9 Market Opportunity Chart of Asia Pacific Rare Disease Drugs Market - By Country, By Value, 2027

9.10 Competitive Scenario of Asia Pacific Rare Disease Drugs Market: By Country

9.11 China Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

9.12 China Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

9.13 Japan Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

9.14 Japan Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

9.15 India Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

9.16 India Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

9.17 South Korea Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value

9.18 South Korea Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

10. Global Rare Disease Drugs Market Dynamics

10.1 Drivers

10.2 Restraints

10.3 Trends

11. Market Attractiveness

11.1 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Drug Class, 2027

11.2 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Therapeutic Area, 2027

11.3 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Patients, 2027

11.4 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Route of Administration, 2027

11.5 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Distribution Channel, 2027

11.6 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Region, 2027

12. Competitive Landscape

12.1 Market Share Analysis

13. Company Analysis

13.1 Takeda Pharmaceutical Company Limited

13.2 Sanofi

13.3 Merck KGaA

13.4 F. Hoffman-La Roche Ltd.

13.5 Pfizer

13.6 Novartis AG

13.7 Bayer Group

13.8 Biogen

13.9 GlaxoSmithKline

13.10 AbbVie Inc.

List of Figures

Figure 1: Global Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 2: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)

Figure 3: Global Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 4: Global Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 5: Prevalence of Rare Disease Drugss in the U.S., EU, and estimated prevalence in China, (In Million)2021

Figure 6: World’s leading causes of death (in millions), 2018

Figure 7: World Population 65 Years & Above (% of Total), 2015-2019

Figure 8: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 9: Global Rare Disease Drugs – Clinical Trial

Figure 10: Global Rare Disease Drugs Market- By Drug Type Market Share, 2021 & 2027

Figure 11: Global Rare Disease Drugs Market- By Biologics, By Value (USD Billion), 2017-2027

Figure 12: Global Rare Disease Drugs Market- By Non-Biologics, By Value (USD Billion), 2017-2027

Figure 13: Global Rare Disease Drugs Market- By Therapeutic Area Market Share, 2021 & 2027

Figure 14: Global Rare Disease Drugs Market- By Infectious Disease, By Value (USD Billion), 2017-2027

Figure 15: Global Rare Disease Drugs Market- By Oncology, By Value (USD Billion), 2017-2027

Figure 16: Global Rare Disease Drugs Market- By Neurological, By Value (USD Billion), 2017-2027

Figure 17: Global Rare Disease Drugs Market- By Metabolic, By Value (USD Billion), 2017-2027

Figure 18: Global Rare Disease Drugs Market- By Others, By Value (USD Billion), 2017-2027

Figure 19: Global Rare Disease Drugs Market- By patients Market Share, 2021 & 2027

Figure 20: Global Rare Disease Drugs Market- By Pediatric, By Value (USD Billion), 2017-2027

Figure 21: Global Rare Disease Drugs Market- By Adults, By Value (USD Billion), 2017-2027

Figure 22: Global Rare Disease Drugs Market- By Route of Administration Market Share, 2021 & 2027

Figure 23: Global Rare Disease Drugs Market- By Oral, By Value (USD Billion), 2017-2027

Figure 24: Global Rare Disease Drugs Market- By Injectable, By Value (USD Billion), 2017-2027

Figure 25: Global Rare Disease Drugs Market- By Distribution Channel Market Share, 2021 & 2027

Figure 26: Global Rare Disease Drugs Market- By Hospital & Retail Pharmacies, By Value (USD Billion), 2017-2027

Figure 27: Global Rare Disease Drugs Market- By Online Pharmacies, By Value (USD Billion), 2017-2027

Figure 28: Global Rare Disease Drugs Market- By Region Market Share, 2021 & 2027

Figure 29: North America Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 30: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 31: North America Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 32: North America Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 33: North America Population ages 65 and above (% of total Population), 2016-2020

Figure 34: North America Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 35: North America Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 36: North America Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 37: North America Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 38: North America Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 39: North America Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 40: Market Opportunity Chart of North America Rare Disease Drugs Market- By Country, By Value (Year-2027)

Figure 41: North America Rare Disease Drugs Market- By Country Market Share, 2021 & 2027

Figure 42: United States Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 43: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 44: United State Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 45: United State Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 46: United States Population aged 65 and above (% of total Population), 2016-2020

Figure 47: United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 48: United State National Institute of Health Spending on Rare Disease Drugs, ( USD Million), 2016-2020

Figure 49: Median U.S. cost per patient per year for top 100 products, 2015-2018

Figure 50: United States Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 51: United States Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 52: United States Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 53: United States Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 54: United States Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 55: Canada Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 56: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 57: Canada Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 58: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 59: Canada Population aged 65 and above (% of total Population), 2016-2020

Figure 60: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 61: Canada Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 62: Canada Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 63: Canada Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 64: Canada Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 65: Canada Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 66: Europe Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 67: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 68: Europe Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 69: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 70: European Countries Population ages 65 and above (% of total Population), 2020

Figure 71: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 72: Europe Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 73: Europe Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 74: Europe Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 75: Europe Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 76: Europe Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 77: Market Opportunity Chart of Europe Rare Disease Drugs Market- By Country, By Value (Year -2027)

Figure 78: Europe Rare Disease Drugs Market- By Country Market Share, 2021 & 2027

Figure 79: Germany Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 80: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 81: Germany Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 82: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 83: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 84: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 85: Germany Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 86: Germany Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 87: Germany Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 88: Germany Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 89: Germany Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 90: United Kingdom Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 91: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 92: United Kingdom Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 93: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 94: United Kingdom Population ages 65 and above (% of total Population), 2016-20

Figure 95: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 96: United Kingdom Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 97: United Kingdom Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 98: United Kingdom Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 99: United Kingdom Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 100: United Kingdom Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 101: France Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 102: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 103: France Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 104: France Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 105: France Population ages 65 and above (% of total Population), 2016-20

Figure 106: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 107: France Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 108: France Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 109: France Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 110: France Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 111: France Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 112: Italy Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 113: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 114: Italy Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 115: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 116: Italy Population ages 65 and above (% of total Population), 2016-20

Figure 117: Italy Trend of expenditure for orphan drugs in Italy from 2016 to 2020 (In Euro USD)

Figure 118: Italy Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 119: Italy Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 120: Italy Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 121: Italy Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 122: Italy Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 123: Asia Pacific Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 124: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 125: Asia Pacific Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 126: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 127: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020

Figure 128: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 129: Asia Pacific Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 130: Asia Pacific Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 131: Asia Pacific Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 132: Asia Pacific Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 133: Asia Pacific Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 134: Market Opportunity Chart of APAC Rare Disease Drugs Market- By Country, By Value (Year -2027)

Figure 135: APAC Rare Disease Drugs Market- By Country Market Share, 2021 & 2027

Figure 136: China Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 137: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 138: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 139: China Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 140: China Population ages 65 and above, by Countries (% of total Population), 2020

Figure 141: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 142: China Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 143: China Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 144: China Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 145: China Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 146: China Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 147: Japan Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 148: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 149: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 150: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 151: Japan Population ages 65 and above (% of total Population), 2016-20

Figure 152: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)

Figure 153: Japan Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 154: Japan Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 155: Japan Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 156: Japan Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 157: Japan Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 158: India Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 159: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 160: India Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 161: India Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 162: India Population ages 65 and above (% of total Population), 2016-20

Figure 163: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 164: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 165: e-pharmacy market in India (USD Million)

Figure 166: India Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 167: India Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 168: India Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 169: India Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 170: India Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 171: South Korea Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)

Figure 172: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 173: South Korea Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 174: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 175: South Korea Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 176: South Korea Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 177: South Korea Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027

Figure 178: South Korea Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 179: South Korea Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027

Figure 180: South Korea Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027

Figure 181: South Korea Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027

Figure 182: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Drug Type (Year -2027)

Figure 183: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Therapeutic Area (Year-2027)

Figure 184: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Patients(Year -2027)

Figure 185: Market Attractiveness Chart of Global Rare Disease Drugs Market- By route of Administration (Year -2027)

Figure 186: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Distribution Channel (Year-2027)

Figure 187: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Region (Year -2027)

Figure 188: Global Rare Disease Drugs company market share (%), 2020

Figure 189: Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)

Figure 190: Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)

Figure 191: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020

Figure 192: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020

Figure 193: Sanofi Sales Revenues, 2016-2020 (USD Million)

Figure 194: Sanofi Gross Profit, 2016-2020 (USD Million)

Figure 195: Sanofi Sales Revenue Split, By Business Segment (%), FY2020

Figure 196: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020

Figure 197: Merck KGaA Sales Revenues, 2016-2020 (USD Million)

Figure 198: Merck KGaA Gross Profit, 2016-2020 (USD Million)

Figure 199: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020

Figure 200: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020

Figure 201: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)

Figure 202: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)

Figure 203: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020

Figure 204: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020

Figure 205: Pfizer Annual Sales Revenue (USD Million), 2016-2020

Figure 206: Pfizer Annual Net Income/Loss (USD Million), 2016-2020

Figure 207: Pfizer sales Revenue, By Geographical Segment (%), FY2020

Figure 208: Novartis Annual Sales Revenue (USD Million), 2016-2020

Figure 209: Novartis Annual Net Income/Loss (USD Million), 2016-2020

Figure 200: Novartis Sales Revenue Split, By Business Segment (USD Billion), FY2020

Figure 211: Novartis Sales Revenue Split, By Geography Segment (%), FY2020

Figure 212: Bayer Group Sales Revenues, 2016-2020 (USD Million)

Figure 213: Bayer Group Net Profit, 2016-2020 (USD Million)

Figure 214: Bayer Group, By Business Segment (%), FY2020

Figure 215: Bayer Group, By Geographical Segment (%), FY2020

Figure 216: Biogen Sales Revenues, 2016-2020 (USD Million)

Figure 217: Biogen Net Profit, 2016-2020 (USD Million)

Figure 218: Biogen, By Business Segment (%), FY2020

Figure 219: Biogen, By Geographical Segment (%), FY2020

Figure 220: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020

Figure 221: GlaxoSmithKline Gross Profit (USD Million), 2016-2020

Figure 222: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020

Figure 223: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020

Figure 224: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020

Figure 225: AbbVie Inc. Net Income (USD Million), 2016-2020

Figure 226: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020

Figure 227: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020

ページTOPに戻る

Table of Contents

Summary

Executive Summary

According to Azoth Analytics research report, the Global Rare Disease Drugs was valued at USD 147.12 Billion in the year 2021. The increasing focus on research activities and the development of novel therapeutic drugs has facilitated the growth of the Rare Disease Drugs market. Additionally, growing product developments is leading to the implementation of technologically driven innovative devices in the diagnosis of rare genetic disorders.

Moreover, favourable government policies aiming at creating awareness pertaining to the Rare Disease treatment are leading to increased adoption of effective treatments of rare disorders. However, there are several factors hindering the efficient and effective clinical trials of drug development of rare disorders including low patient numbers, limited understanding of pathology and progression, and lack of established endpoints. Therefore, several regulatory bodies are engaged in implementing regulatory standards for drug approval for Rare diseases to ensure patient safety and efficacy of drugs.

Furthermore, improved detection and increased rates of diagnosis of Rare diseases are likely to contribute to rising costs. While the humanitarian benefits of Rare Disease therapies are indisputable, concerns regarding high treatment costs play a meaningful role in how payers administer and manage healthcare benefits that ultimately dictate patient access to orphan drugs. Moreover, the biological drugs are used for treating Rare diseases such as cancer with fewer side effects that have a high prevalence rate in the developed world.

Scope of the Report

• The report presents the analysis of the Rare Disease Drugs market for the historical period of 2017-2021 and the forecast period of 2022-2027.

• The report analyses the Rare Disease Drugs Market by Value (USD Billion).

• The report analyses the Rare Disease Drugs Market by Drug Type (Biologics, Non-Biologics).

• The report analyses the Rare Disease Drugs Market by Therapeutic Area (Infectious Disease, Oncology, Neurology, Metabolic, Others).

• The report analyses the Rare Disease Drugs Market by Patients (Pediatric, Adults).

• The report analyses the Rare Disease Drugs Market by Route of Administration (Oral, Injectable).

• The report analyses the Rare Disease Drugs Market by Distribution Channel (Hospital & Retail Pharmacies, Online Pharmacies).

• The Global Rare Disease Drugs Market has been analysed By Region (North America, Europe, Asia Pacific and LAMEA).

• The Global Rare Disease Drugs Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, India, South Korea).

• The attractiveness of the market has been presented by region, by Drug Type, by Therapeutic area, by patients, by Route of Administration and by Distribution Channel

• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development.

• The companies analysed in the report include Takeda Pharmaceutical Company Limited, Sanofi, Merck KGaA, F. Hoffman-La Roche Ltd., Pfizer, Novartis AG, Bayer Group, Biogen, GlaxoSmithKline, AbbVie Inc.

Key Target Audience

• Rare Disease Drugs Manufacturers

• Healthcare and Pharmaceutical Companies

• Consulting and Advisory Firms

• Government and Policy Makers

• Regulatory Authorities

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（通信回線）の最新刊レポート

Azoth Analytics 社の最新刊レポート

本レポートと同じKEY WORD（administration）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

希少疾患治療薬の世界市場（2022年版） - 薬剤タイプ、治療領域、患者、投与経路、流通チャネル、地域別、国別の分析（2022年版）。市場インサイト、COVID-19の影響を考慮した予測（2022-2027年）。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（通信回線）の最新刊レポート

Azoth Analytics 社の最新刊レポート

本レポートと同じKEY WORD（administration）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?